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Abstract: To develop potential next-generation metal anticancer agents, 
we designed and synthesised five Cu(II) 2-pyridine-thiosemicarbazone 
complexes by modifying the hydrogen atom at the N-4 position of ligands, 
and then investigated their structure-activity relationships and 
anticancer mechanisms. Modification of the N-4 position with different 
groups caused significant differences in cellular uptake and produced 
superior antitumor activity. Cu complexes arrested the cell cycle at S 
phase, leading to down-regulation of levels of cyclin and cyclin-
dependent kinases and up-regulation of expression of cyclin-dependent 
kinase inhibitors. Cu complexes exerted chemotherapeutic effects via 
activating p53 and inducing production of reactive oxygen species to 
regulate expression of the B-cell lymphoma-2 family of proteins, causing 
a change in the mitochondrial membrane potential and release of 
cytochrome c to form a dimer with apoptosis protease activating factor-1, 
resulting in activation of caspase-9/3 to induce apoptosis. In addition, 
Cu complexes inhibited telomerase by down-regulating the c-myc regulator 
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·Five Cu(II) complexes modified at the N-4 position of 
thiosemicarbazones were synthesized. 
·Cu complexes have high anticancer activity. 
·Cu complexes arrest the cell at S-phase and inhibit the action of 
telomerase. 
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To develop potential next-generation metal anticancer agents, we 
designed and synthesised five Cu(II) 2-pyridine-thiosemicarbazone 
complexes by modifying the hydrogen atom at the N-4 position of ligands, 
and then investigated their structure-activity relationships and anticancer 
mechanisms. Modification of the N-4 position with different groups caused 
significant differences in cellular uptake and produced superior antitumor 
activity. Cu complexes arrested the cell cycle at S phase, leading to 
down-regulation of levels of cyclin and cyclin-dependent kinases and 
up-regulation of expression of cyclin-dependent kinase inhibitors. Cu 
complexes exerted chemotherapeutic effects via activating p53 and inducing 
production of reactive oxygen species to regulate expression of the B-cell 
lymphoma-2 family of proteins, causing a change in the mitochondrial 
membrane potential and release of cytochrome c to form a dimer with 
apoptosis protease activating factor-1, resulting in activation of caspase-9/3 
to induce apoptosis. In addition, Cu complexes inhibited telomerase by 
down-regulating the c-myc regulator gene and expression of the human 









Since cisplatin began being used as an anticancer drug in the 1970s, most 
chemotherapy drugs in clinical and preclinical studies are platinum-based 
complexes [1-8]. However, drug resistance and adverse side effects were 
common in cisplatin chemotherapy, therefore, scientists focused on 
developing novel metal complexes with better antitumor activity, fewer side 
effects, and reduced drug resistance to replace cisplatin therapy [9]. In recent 
years, several transition-metal complexes have been developed as antitumor 
treatments, and the most promising of these complexes are based on copper 
[10, 11], ruthenium [12, 13], and gallium [14-16]. The coordination 
complexes of ruthenium and gallium have also entered clinical trials [17-19].  
Copper, as the active centre of many enzymes, plays an important role in 
development and function of human organs and tissues [20-22]. To date, 
copper-based complexes have been extensively synthesised and investigated 
as anticancer agents because of their high antitumor activity and advantages 
relative to other metal anticancer complexes [23-38]. Thiosemicarbazones 
are formed by a condensation reaction of thiosemicarbazide and aldehydes 
or ketones. Pharmacological studies have demonstrated that 
thiosemicarbazones present a variety of biological activities [39, 40]. 
Thiosemicarbazones contain nitrogen and sulphur atoms with strong 
coordination ability, and can form various complexes with novel structures. 




anticancer activity [41-44]. Currently, copper complexes derived from 
thiosemicarbazides have become a potential research hotspot [45-47]. 
Copper thiosemicarbazone complexes can produce reactive oxygen species, 
and act against topoisomerase II, DNA, and other potential targets in the 
nucleus [48]. Hence, the copper thiosemicarbazone complex is a promising 
candidate for developing ideal non-platinum and multi-target antitumor 
drugs. 
Considering above factors, we synthesised five Cu(II) complexes with 
ligand/Cu at a ratio of 1:1 via modification at the N-4 position (Scheme 1), 
and characterised their structures using X-ray crystallography, elemental 
analysis, infrared spectroscopic analysis, and electrospray ionization-mass 
spectrometry. Subsequently, we investigated their associated 
structure-activity relationship. The five complexes identified demonstrated 
marked toxicity. Finally, we confirmed their multi-target anticancer 
mechanisms. The selected complex C4 caused apoptosis via the 
p53-mediated mitochondrial pathway and telomerase inhibition by 
regulating the expression of c-myc regulator gene and hTERT. 
2 Results  
2.1 Design and structure of five Cu complexes 
Previous research showed that aldehyde-thiosemicarbazones were more 
advantageous than ketone-thiosemicarbazones, the latter being less active 
and toxic [39]. These compounds present a variety of biological activities, 




different derivatives, such as those containing hexatomic or heptatomic rings, 
or monocyclic or bicyclic derivatives. Based on these findings, we selected 
2-pyridine-thiosemicarbazone to design and synthesise five novel Cu(II) 
complexes by modification of the N-4 position.  
The complexes C1-C5 were prepared via the copper salt reaction with 
L1-L5, respectively, in methanol, stirred, and refluxed at 65 °C for 6 h. The 
solvent evaporation method was used to prepared crystals. Furthermore, the 
structures of the Cu(II) complexes were identified by X-ray crystallography 
as shown in Table 1. The crystal structure identified showed that the copper 
centres of the C1, C2, and C3 complexes were tetra-coordinated by two 
nitrogen atoms, one sulphur atom of chelating Schiff base ligand, and one 
halogen atom or one nitrate ion. Moreover, the copper centres of C4 and C5 
were penta-coordinated by two nitrogen atoms, one sulphur atom of 
chelating thiosemicarbazone, one halogen atom or one nitrate ion, and one 
methanol molecule (Figure 1). The five complexes crystallise with different 
space groups, P-1, C2/c, P21/c, P-1, and P-1, respectively. The selected 
bond lengths are shown in Table S1.We found no obvious vibration for the 
Cu1-N1 bond (2.017Å-2.048Å), Cu1-N2 bond (1.959Å-1.994Å), and 
Cu1-S1 bond (2.2366Å-2.2744Å).The angle of N-Cu-N was in the range of 
80.39-81.19˚(C1-C5). The angle of N(1)-Cu-S was in the range of 
161.46-164.10˚ (C1-C5). The angle of N(2)-Cu-S was in the range of 
83.33-83.68˚, and there were no major changes in the bond angles for each 
complex.  




UV-Vis spectroscopy was employed to study the stability of complexes 
[49]. Briefly, the complexes were dissolved in the PBS for 0, 24, and 48 h, 
and detected by UV-Vis spectroscopy. The results demonstrated that the 
UV-Vis spectra of the five complexes show no significant changes in 
spectral characteristics and peak absorption over time (Figure S1), which 
suggested that the five complexes are stable in PBS for 48 hours at room 
temperature. 
2.3 Structure-activity relationships of Cu complexes in vitro 
Six cell lines including a normal liver cell line (MGC80-3, HepG2, 
SK-OV-3, NCI-H460 and HL-7702) were employed to study the antitumor 
activity of the 2-pyridine-thiosemicarbazone ligands and their complexes in 
vitro.IC50 values were determined using the colourimetric assay, MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium). 
As shown in Table 2, Cu(II) complexes are more cytotoxic to cancer cells 
relative to the corresponding ligand because of chelation of ligand to Cu
2+
. 
All Cu(II) complexes exhibited considerable antitumor activity with IC50 
values from 0.84 to 12.11 µM. Compared with C1, the activity of the 
complexes increased by 9-, 11- and 10- fold via introduction of a benzene 
ring (C2),formation of a piperidine ring with N-4 (C3), or apyrrolidine ring 
(C5) at the N-4 position in MGC80-3 cells. Introduction of two methyl 
groups at N-4 carrying a lead group increased the activity by more than 
14-fold, which showed that the modified complexes have better activity 
against selected tumour cells. 




intracellular copper contents were 11.94-20.81nmol (Figure 2). Relative to 
C1, the total concentration of the N4-modified complexes that were 
absorbed into cells increased to 51.21%, 40.59%, 74.28%, and 41.89%, 
respectively. However, there were no significant differences in the 
concentration of each complex distributed to the mitochondria (3.24-3.73 
nmol), whereas the concentration in the nucleus increased to 31.85%, 
28.38%, and 27.91% after the cells were treated with C3, C4, andC5, 
respectively, for 24 h. Similarly, the concentration of C2-C5 in the 
cytoplasm increased significantly resulting from modification at the N-4 
position (Figure 2). These results showed that modifications at the N-4 
position affect the amount of complex absorbed into cells and can lead to 
differences in antitumor activity.  
2.4 Confirmation of anticancer mechanisms of Cu complexes 
Apoptosis is a complex process with multiple pathways regulated by 
multiple proteins. The p53 protein, a nuclear transcription factor, plays an 
important role in regulating a wide variety of genes [50-52].A downstream 
response factor of p53, p21 expression is significantly increased following 
p53 activation, leading to cell cycle arrest. In the mitochondria-induced 
apoptosis pathway, p53 can activate the apoptosis regulator, Bcl-2-like 
protein 4, Bax, to form a heterodimer with Bcl-2 as an apoptotic activator 
[53, 54]. Bax increases the anion channel open probability, and induces loss 
of mitochondrial membrane potential (Δψm), ultimately promotes release of 
cytochrome c (Cyt c). In addition, p53 can activate the Bcl-2-associated 




form a complex, and promote release of Cyt c [55, 56]. In the nucleus, p53 
can bind the promoter of c-myc and promote histonedeacetylation, thereby 
inducing the repression of c-myc [57].  
2.4.1 P53-regulates the levels of cell cycle regulators and promotes the cell 
cycle  
Cell cycle was examined by flow cytometry. Cell cycle analysis clearly 
shows that the C1 complex blocks the cell cycle in the G1 phase (Figure 3A). 
The cell population in the G1 phase increased to 11% and 12% after 
treatment with 6 µM and 12 µM of the C1 complex, respectively. The C4 
complex arrested the cells in the G1/S phase when used at a concentration of 
0.4 µM and in the S phase with a concentration of 0.8 µM. In comparison 
with control cells, the G1/S populations increased 8.55% and 1.36% after the 
cells were treated with C4 at 0.4µM, and S populations increased 14.07% 
after the cells were treated with C4 at 0.8 µM. 
The cell cycle is regulated by cyclin and cyclin-dependent kinases 
(CDKs); cyclin A, cdc25 A, and CDK2, which are closely associated with S 
phase. Cdc25 A activates CDK2 by dephosphorylation and promotes cell 
cycle progression [58, 59]. Western blot analysis using anti-cdc25A, cyclin 
A, and CDK2 antibodies was used to determine whether the selected 
complexes affect expression of related proteins in MGC80-3 cells. As shown 
in Figures 3B and C, expression of these three proteins decreased at varying 
degrees. Therefore, we further examined expression of p21 and p27 protein 
levels, which act as cyclin-dependent kinase inhibitors. As showed in 




after treatment with the C4 complex for 24 h. In particular, p21 
demonstrated a 6-fold increase compared to the control group.  
2.4.2 P53-regulates the levels of c-myc, hTERT, and telomerase inhibition 
Telomerase is over-expressed in most tumour cells, while little to no 
expression is found in normal cells [60, 61]. C-myc is a member of the myc 
family of proteins, which are strong proto-oncogenes and regulate a range of 
genes including those mediating cell proliferation and apoptosis. C-myc is 
also the first transcription factor found to regulate the expression of hTERT, 
an enzyme considered to act as a rate limiting factor for telomerase 
activation. As such, inhibition of telomerase activity by regulating c-myc 
and hTERT gene expression is considered a new direction in antitumor 
research [62-65]. Western blot results showed that levels of c-myc were 
reduced by 88.08% with 12 µM C1 complex relative treatment relative to 
control levels (Figures 4A and B). However, there were no changes when 
the cells were treated with 6 µM of the C1 complex. In contrast, c-myc 
levels were significantly reduced by 77.63% and 80.57%when cells were 
treated with the C4 complex at 0.4 and 0.8 µM, respectively. In addition, 
expression levels of hTERT significantly decreased by 72.95% and 78.27% 
after the cells were treated with the C4 complex at 0.4 and 0.8 µM, 
respectively. In contrast, this reduction was not particularly obvious after 
treatment with the C1 complex (6 or 12 µM). Measurement of telomerase 
inhibition using the polymerase chain reaction (PCR)-based telomeric repeat 
amplification protocol (TRAP) assay revealed that the complexes C1 and C4        




(Figure 4C).  
2.4.3 P53-mediates anticancer mechanisms via mitochondrial pathways 
Proteins belonging to the Bcl-2 family play a key role in mediating the 
mitochondrial apoptosis pathway by controlling mitochondrial membrane 
permeability [66, 67]. The p53 protein can up-regulate the pro-apoptotic 
proteins Bad and Bax, and down-regulate expression of Bcl-2, resulting in 
the dissipation of Δψm and release of Cyt c [68, 69], which is a key step in 
apoptosis. Moreover, Cyt c forms a dimer with apoptosis-related factor 1 
(Apaf-1) and activates caspase-3/9. Flow cytometry results showed that cells 
treated with C1 and C4 complexes can lead to collapse of the Δψm. 
Compared with the 3.24% Δψm of control cells, the Δψm decreased to 
18.60% and 54.90% after treatment with the C1 complex at 6 µM and 12 
µM, respectively. Similarly, the Δψm decreased to 12.30% and 52.90% after 
treatment with the C4 complex at0.4µM and 0.8 µM, respectively (Figure 
S3). Importantly, the decrease in Δψm was positively correlated with the dose 
of complex administered. Western blot results showed that levels of Apaf-1, 
Bad, Bax, and Cyt c increased significantly after MGC80-3 cells were 
treated with complex C4, while Bcl-2 levels decreased (Figures 5A and B). 
Meanwhile, we used the fluorescent 2,7-dichlorofluorescein (DCF) probe to 
evaluate the ability of the selected complexes to catalyse production of 
intracellular ROS in MGC80-3 cells, which can promote expression of 
apoptotic proteins as second messengers and induce opening of the 
mitochondrial permeability transition pore [70-73]. After cells were exposed 




h, cells produced a green fluorescence characteristic of activation (Figure 
S3). 
Downstream of the mitochondrial apoptotic pathway, caspase 3 acts as 
an apoptotic signalling molecule as caspase 9 activation leads to caspase 3 
activation [74, 75]. In this experiment, flow cytometry was used to examine 
activation of caspase-9/3. As shown in Figure S4, activated caspase-9 levels 
increased 24.93% and 31.19% after treatment with the C1 (12 µM) and C4 
(0.8 µM) complexes. Similarly, activated caspase-3 levels increased 5.96% 
and 10.56%, respectively.  
Our results showed that cells treated with two doses of the selected 
complexes underwent dose-dependent late apoptosis, with the percentages of 
the apoptotic MGC80-3 cells increasing with dose by 5.04% and 18.85% 
when treated with the C1 complex at6 µM and 12 µM, respectively, and by 
2.65% and 29.84% when treated with the C4 complex (0.4 or 0.8 µM) as 
compared to the control group (Figure 5C).  
2.4.4 The action of DNA cleavage studies 
Many studies have shown that Schiff base copper complexes can target 
DNA [76, 77]. Therefore, we investigated the effects of C1 and C4 on 
Pbr322 plasmid DNA by gel electrophoretic separations. The results showed 
that a relatively high concentration of C1 did not significantly cleave DNA. 
In contrast, C4 relaxed Form I (supercoiled form) of DNA into Form II at 





A common approach in drug discovery is to find a promising lead drug 
and modify the structure of the compound to improve performance. 
Structural modification can change absorption, extend duration of effect, 
reduce toxicity, and increase solubility, among other potential benefits.  
Discovery of novel high-efficiency and low-toxicity antitumor agents 
from thiosemicarbazone derivatives and their complexes is a field receiving 
increasing amounts of attention. Studies have shown that modification at the 
N-4 position of thiosemicarbazides with moieties such as introducing 
carboxyl groups, phenyl group, forming a 5- or 6-membered aromatic 
heterocycle, etc. can improve anti-tumour potential of these molecules. Our 
experiments evaluating cellular uptake showed that complexes modified at 
the N-4 position were more readily absorbed into cells and distributed to the 
nucleus than the original complex, which may indicate the mechanisms 
underlying the increase in activity of the N-4 modified complexes in our 
studies.  
Based on the complexity of tumour development, there are crossovers 
and compensations between signalling pathways for most tumours to 
maintain their growth and survival. In clinical studies, the effects of targeted 
therapy against a single pathway are often unsatisfactory, with activation of 
alternative pathways as one of the mechanisms for this effect. Multi-target 
drug development can achieve synergistic effects and overcome drug 
resistance by inhibiting multiple signalling pathways or multiple molecules 
upstream and/or downstream of one pathway, providing therapeutic action 




that the Cu N-4 modified 2-pyridine-thiosemicarbazone complexes could 
significantly up-regulate p21 and arrest MGC80-3 cells at S phase, and 
induce apoptosis by regulating Δψm via down-regulation of p53 to regulate 
expression of Bcl-2 family proteins. In addition, since telomerase is 
considered a promising target for novel anticancer drugs, C4 was shown to 
inhibit telomerase activity by significantly inhibiting the expression of 
c-myc and hTERT. Therefore, the thiosemicarbazone-based Cu complexes 
show promise as an avenue for development of multi-target anticancer metal 
pro-drugs.  
4 Conclusion 
To develop the next-generation metal-based anticancer agents, we 
designed and optimised Cu(II) tridentate 2-pyridine-thiosemicarbazone 
complexes by modifying the N-4 position in thiosemicarbazones. The Cu 
complexes not only confer marked anticancer activity, but can also directly 
induce cancer cell apoptosis through multiple mechanisms, including 
regulation of proteins related to the cell apoptosis pathway, and inhibition of 
telomerase activity. Our results suggested that the Cu(II) tridentate 
2-pyridine-thiosemicarbazone complexes have potential as promising 
multi-target anticancer metal lead drugs. 
5 Materials and Methods 
All chemicals were provided by Energy Chemical Company (Shanghai, 
China).All cell lines (MGC80-3, SK-OV-3, NCI-H460, HepG2 and 
HL-7702) were provided by the Shanghai Institute for Biological Science 




JC-1, the reactive oxygen species assay kit, the mitochondria isolation kit, 
and nuclei isolation kit were purchased from Beyotime (Jiangsu, China). 
Fluorescein active caspase-3 and -9 staining kits were purchased from 
BioVision (Milpitas, CA). The telomerase activity assay kit was provided by 
Genmed (Minneapolis, MN). The antibodies used in western blot were 
provided by Abcam (Cambridge, UK). 
5.1 Synthesis of ligands 
The L1-L5 ligands were prepared using previously published methods 
[78]. In brief, 2-pyridinecarboxaldehyde (10 mmol) MeOH solution was 
added to the corresponding equimolar thiosemicarbazides (10 mmol) and 
stirred for 6 h at 60℃, and the ligands were precipitated and filtered to 
obtain the L1−L5 ligands. The ligands were purified by re-crystallization. 
All ligands were characterised by elemental analysis, infrared spectral 
analysis, 
1
H-NMR and electrospray ionization-mass spectrometry (ESI-MS; 
Supporting Information, Figures S6−S15). 
N-methyl-2-(pyridin-2-ylmethylene)hydrazinecarbothioamide(L1): yield 
(1.52 g, 78%). Anal. Calcd (%) for C8H10N4S: C, 49.46; H, 5.19; N, 28.84; S, 
16.51. Found: C, 49.23; H, 5.02.; N, 28.68, S, 16.43. IR (KBr, cm
-1
): 3450, 
3288, 3138, 2943, 1528, 1433, 1319, 1267, 1247, 1151, 1109, 1088, 1038, 
997, 928, 885, 779, 675, 623, 608, 520, 414. 
1
H NMR (400 MHz, DMSO) δ 









(1.81 g, 70%). Anal. Calcd (%) for C13H12N4S:C, 60.91; H, 4.72; N, 21.86; S, 
12.51. Found: C, 60.77; H, 4.61; N, 21.73; S, 12.58.IR (KBr, cm
-1
):3307, 
3124, 2952, 1597, 1551, 1524, 1468, 1326, 1287, 1256, 1189, 1160, 1109, 
1077, 997, 942, 923, 754, 692, 622, 506, 480. 
1
H NMR (400 MHz, DMSO) 
δ 12.03 (s, 1H), 10.25 (s, 1H), 8.59 (ddd, J = 4.9, 1.6, 0.9 Hz, 1H), 8.45 (d, J 
= 8.0 Hz, 1H), 8.20 (s, 1H), 7.85 (td, J = 7.7, 1.4 Hz, 1H), 7.59–7.53 (m, 2H), 




N'-(pyridin-2-ylmethylene)piperidine-1-carbothiohydrazide(L3): yield (1.86 
g, 75%). Anal. Calcd (%) for C12H16N4S: C, 58.04; H, 6.49; N, 22.56; S, 
12.91. Found: C, 58.04; H, 6.49; N, 22.56; S, 12.91. IR (KBr, cm
-1
): 3431, 
3141, 2929, 1497, 1349, 1281, 1010, 997, 894, 774, 619, 536, 515, 446, 
411.
1
H NMR (400 MHz, DMSO) δ 11.25 (s, 1H), 8.58 (dt, J =4.8, 1.2 Hz, 
1H), 8.17 (s, 1H), 7.87–7.83 (m, 2H), 7.37 (d, J =4.1 Hz, 1H), 3.88 (s, 4H), 




yield (1.73 g, 83%). Anal. Calcd (%) for C9H12N4S: C, 51.90; H, 5.81; N, 






3431, 3125, 2972, 1553, 1410, 1238, 1154, 1103, 1078, 1056, 900, 875, 778, 
737, 620, 583, 513. 
1
H NMR (400 MHz, DMSO) δ 11.71 (s, 1H), 8.67 (d, J 
= 4.3 Hz, 1H), 8.57 (d, J = 4.6 Hz, 1H), 8.26 (d, J = 8.0 Hz, 1H), 8.09 (s, 





g, 75%). Anal. Calcd (%) for C11H14N4S: C, 56.38; H, 6.02; N, 23.91; S, 
13.68. Found: C, 56.22; H, 6.11; N, 23.83; S, 13.62.IR (KBr, cm
-1
): 3435, 
3018, 2927, 2856, 2768, 1604, 1567, 1498, 1435, 1360, 1308, 1274, 1249, 
1222, 1192, 1164, 1134, 1014, 951, 918, 885, 781, 714, 624, 518, 
419.
1
HNMR (400 MHz, DMSO) δ 11.24 (s, 1H), 8.60–8.54 (m, 1H), 8.20 (s, 
1H), 7.90–7.81 (m, 2H), 7.36 (ddd, J = 6.7, 4.9, 1.4 Hz, 1H), 3.76 (s, 4H), 
1.90 (s, 4H).ESI-MS: m/z = 233.09 [C11H14N4S−H]
－
. 
5.2 Synthesis and characterization of Cu(II) complexes 
The ligands (0.1 mmol) and the copper salts solution (0.1 mmol) were 
added into 20ml MeOH solution and refluxed for 6 h at 65 °C. The reaction 
solution was placed at room temperature to obtain crystals, and the 
complexes were purified by re-crystallization. The new complexes were 
[Cu(P4mT)Cl] (C1), [Cu(P4pT)NO3] (C2), [Cu(P3piT)Br] (C3), 
[Cu(P44mT)(CH3OH)Br] (C4), and [Cu(P3pyT)(CH3OH)Cl] (C5). 
Elemental analysis, infrared spectral analysis, and ESI-MS were employed 





[Cu(P4mT)Cl] (C1): yield (23.96 mg, 82%). Anal. Calc. for C8H9ClCuN4S: 
C, 32.88; H, 3.10; N, 19.17; S, 10.97. Found: C, 32.71; H, 3.01; N, 19.29; S, 
10.81. IR (KBr, cm
-1
): 3451, 1637, 1595, 1537, 1469, 1357, 1306, 1283, 
1226, 1121, 1043, 608, 520. MS m/z: 334.0 [M+H+C2H3N]
－
. 
[Cu(P4pT)NO3] (C2): yield (27.04 mg, 71%). Anal. Calc. for C13H11Cu 
N5O3S: C, 41.00; H, 2.91 N, 18.39; S, 8.42. Found: C, 41.13; H, 2.82 N, 
18.25; S, 8.31. IR (KBr, cm
-1
): 3328, 1600, 1544, 1455, 1433, 1383, 1284, 
1128, 747. MS m/z: 318.00 [M−NO3]
+
. 
[Cu(P3piT)Br] (C3): yield (28.92 mg, 74%). Anal. Calc. for 
C12H15BrCuN4OS: C, 36.88; H, 3.87; N, 14.34. Found: C, 36.76; H, 3.95; N, 
14.26. IR (KBr, cm
-1
) 3435, 1629, 1584, 1563, 1463, 1432, 1285, 1219, 
11084, 1041, 991, 953, 863, 777, 618, 500, 405. MS m/z: 390.04[M−H]
－
. 
[Cu(P44mT)(CH3OH)Br] (C4): yield (29.09 mg, 76%). Anal. Calc. for 
C10H15BrCuN4OS: C, 31.46; H, 3.70; N, 14.68; S, 8.40. Found: C, 31.34; H, 
3.83; N, 14.58; S, 8.31. IR (KBr, cm
-1
) 3433, 2897, 1581, 1519, 1466, 1415, 
1280, 1149, 906, 782, 644, 613. MS m/z : 350.01 for [M−H−CH3OH]
－
. 
[Cu(P3pyT)(CH3OH)Cl] (C5): yield (28.78 mg, 79%). Anal. Calc. for 
C12H17ClCuN4OS: C, 39.67; H, 4.44; N, 15.42; S, 8.82. Found: C, 39.54; H, 
4.32; N, 15.56; S, 8.73. IR (KBr, cm
-1





A diffractometer was used to collect X-ray diffraction data for the five 




the complexes [79].The atoms excluding hydrogen atom are refined 
anisotropically. The hydrogen atom is theoretically added at the appropriate 
position by Olex2.The crystal data of all copper complexes are listed in 
Table 1. Selected bond lengths (Ẳ) and angles (degrees) are given in Tables 
S1-S2. 
5.4 In vitro cytotoxicity assay 
Stock solutions (10 mM) of the ligands and copper complexes were 
prepared by dissolving the complexes in DMSO, and diluted to various 
concentrations with PBS. The MTT assay was employed to investigate cell 
toxicity [80]. Briefly, all cells were seeded in 96-well plates. After 
incubation for 24 h, the complexes were added to the culture medium at 
various concentrations and the cells were incubated for 48 h. MTT solution 
(10µL) was added to each well and incubated for 4 h. One-hundred 
microliters of DMSO was added to each well after the culture medium was 
removed. The absorbance was measured by an enzyme-labelling instrument 
and IC50 values were calculated.  
5.5 Cellular uptake 
To investigate the underlying mechanisms of the enhanced activity of the 
modified complexes, ICP-MS was performed to detect distribution of the 
complexes in cancer cells [81]. Briefly, the selected cells were treated with 
the five complexes at the same dose (0.8 µM) for 24 h, the mitochondria 
isolation kit and nuclei isolation kit were used to separate and extract the 
mitochondrial membrane fraction, nuclear fraction, and cytoplasm. 




5.6 TRAP assay 
To investigate inhibition of telomerase activity by the selected 
complexes, a TRAP-Silver stain assay was performed [82]. Briefly, 1×10
6
 
MGC80-3 cells were treated with C1 (12 µM) and C4 (0.8 µM) for 24 h. 
The cells were collected and telomerase was extracted according to the kit 
instructions. Five microliters of telomerase reaction mixture added to a 
final volume of 50 µL for PCR amplification. The sample was incubated at 
30 °C for 30 minutes, followed by 30 cycles of 92 °C for 30 seconds, 52 °C 
for 30 seconds, and 72 °C for 30 seconds. Non-denaturing acrylamide gel 
electrophoresis (12%; 19:1) was used to isolate proteins at 180 V for 40 
minutes and 220 V for 80 minutes. Gels were stained with 0.2 % 
AgNO3andbands developed with sodium bicarbonate. 
5.7 Cell cycle analysis 
To study the effects of the complexes on the cell cycle of tumours, we 
used flow cytometry to detect changes in cell cycle distribution before and 
after drug treatment. Briefly, MGC80-3 cell suspension (1×10
5
 cells/mL) 
was plated in 10-mm culture dishes and incubated for 12 h, then treated with 
C1 (6 or 12 µM) and C4 (0.4 or 0.8 µM) for 48 h. The cells were harvested 
and washed with cool PBS solution. Cells were fixed in ice-cold 70% 
ethanol solution and stored at -25 °C for 24 h. The cells were centrifuged 
and incubated with RNase A for 30 min. The cell cycle distribution was 
detected with a flow cytometer. 
5.8 Intracellular measurements of ROS 




probe dichloro-dihydro-fluorescein diacetate (H2DCFH-DA) and visualised 
by fluorescence microscopy. The cells seeded in 6-well plates were exposed 
to C1 (6 or 12 µM) and C4 (0.4 or 0.8 µM) for 24 h. Cool PBS solution was 
used to wash the cells twice, and the cells were incubated in serum-free 
medium containing H2DCFDA (2 mM), and finally washed twice using 
serum-free medium. A fluorescence microscope was used to observe the cell 
fluorescence. 
5.9 Measurement of the Δψm 
A flow cytometer employing JC-1 probe was used to detect changes in 
Δψm in MGC80-3 cells. The cells in 6-well plates were exposed to C1 (6 or 
12 µM) and C4 (0.4 or 0.8 µM) for 24 h, harvested, and washed twice with 
cool PBS solution. JC-1 stock solution was added to the cells and incubated 
for 30 minutes. A flow cytometer was used to detect the fluorescence of 
separated cells. 
5.10 DNA cleavage studies 
Briefly, supercoiled plasmid pBR322 DNA, Tris-HCl buffer and 
different concentrations of C1 and C4 (25, 100, and 250 μM) were mixed 
and incubated in a tube at 37 °C for 3 h. Subsequently, the loading buffer 
was added into the mixture. The mixture was loaded onto 1% agarose gel 
containing 1% (v/v) goldView II, and analysed by gel electrophoresis in 1X 
TBE buffer at 80 V. 
5.11 Western blot analysis 




µM) and C4 (0.4 or 0.8 µM) for 24 h. A lysis buffer was employed to 
lysethe harvested cells. 12% SDS–polyacrylamide gel electrophoresis was 
employed to separate proteins. Proteins were transferred to polyvinylidene 
difluoride (PVDF) membranes, and the membranes were incubated with 
different antibodies. A western blot detection system was used. Gray scale 
analysis was used for quantitative analysis of bands. 
5.12 Determination of caspase-3/9 activity  
Activation of caspase-3/9 was measured by flow cytometry employing a 
Fluoresce in Active Caspase-3/9 Staining Kit. Appropriate cells in six well 
plates were exposed for 24 h to C1and C4 at 12 µM and 0.8µM, respectively. 
Cells were harvested and washed with cool PBS solution, plus wash buffer 
containing FITC-DEVD-FMK, and incubated for 30 minutes. A flow 
cytometer was employed to detect caspase-3/9 activity. 
5.13 Cell apoptosis assay 
Annexin V/PI double staining was employed to investigate cell apoptosis, 
which was analysed by flow cytometry. Briefly, after treatment with C1 (6 
or 12 µM) and C4 (0.4 or 0.8 µM) for 24 h, the cells were harvested and 
re-suspended. Annexin V-FITC and PI were added and the cells were 
incubated for 15 minutes and analysed by flow cytometry. The data were 
then analysed using FlowJo software. 
5.14 Statistical analysis 
Student's t-test was employed to evaluate significant differences. The 
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Scheme 1 Synthetic routes for C1-C5 
Figure 1 The chemical structures of C1-C5. 
Figure 2 Metal contents in whole MIG80-3 cells deducting blank control 
and different fraction was measured by ICP-MS after the MIG80-3 cells 
were treated with C1-C5 (0.8 µM) for 24 h, The values were relative to C1 
(*P < 0.05). 
Figure 3(A) Effect of the cell cycle treated with (a) control; (b) C1-6µM; (c) 
C1-12µM); (d) C4-0.4µM; (e) C4-0.8µM for 48 h. (B) Western blot analysis 
the levels of Cdc25A, Cyclin A2, CDK2, p27 and p21. (C) Densitometric 
analysis of the expression of Cdc25A, Cyclin A2, CDK2, p27 and p21.The 
percentage values were relative to the control (*P < 0.05). 
Figure 4 (A) The protein levels of c-myc and hTERT in MGC80-3 cells 
treated with C1 (6/12 µM) and C4 (0.4/0.8 µM) for 24 h, respectively. (B) 
Densitometric analysis of c-myc and hTERT (*P < 0.05). (C)The influence 
on the telomerase activity in the MGC80-3 cells treated with C1 (12 µM) 
and C4 (0.8 µM). 
Figure 5 (A) Western blot analysis the levels of Apaf-1, Bcl-2, Bax, Bad, 
p53 and Cyt C after treated with (6/12 µM) and C4 (0.4/0.8 µM) for 24 h. (B) 
Densitometric analysis of the expression of Apaf-1, Bcl-2, Bax, Bad, p53 
and Cyt C. The percentage values are those relative to the control (*P < 
0.05). (C) Apoptosis of MIG80-3 cells treated with C1 and C4. (a) Control; 









Identification code C1 C2 C3 C4 C5 
Empirical formula C8H9ClCuN4S C13H11CuN5O3S C12H15BrCuN4S C10H15BrCuN4OS C12H17ClCuN4OS 
Formula weight 292.24 380.87 390.79 382.77 364.35 
Temperature/K 296.15 296.15 296.15 296.15 296.15 
Crystal system triclinic monoclinic monoclinic triclinic triclinic 
Space group P-1 C2/c P21/c P-1 P-1 
a (Å) 6.7305(9) 17.627(2) 10.992(7) 7.6723(4) 7.464(3) 
b (Å) 9.306(12) 16.055(2) 14.559(10) 9.6352(5) 9.748(4) 
c (Å) 9.439(10) 13.663(18) 9.122(6) 9.7622(5) 10.352(5) 
α (o) 106.595(10) 90 90 101.585(5) 93.078(6) 
β (o) 106.835(10) 129.523(2) 95.173(10) 96.629(5) 95.765(6) 
γ (o) 95.062(11) 90 90 95.743(5) 98.652(6) 
V (Å3) 532.78(12) 2982.5(7) 1453.8(17) 696.58(7) 739.0(6) 
Z 2 8 4 2 2 
ρcal/cm
3 1.822 1.696 1.785 1.825 1.637 
µ(Mo-Kα) (mm-1) 2.465 1.627 4.385 4.579 1.799 
F(000) 294 1544 780 382 374 
Data/restraints/param
eters 
1869/0/137 3059/0/208 2951/0/179 2450/0/170 3031/0/186 
Goodness-of-fit on F2 1.105 0.873 0.84 1.069 1.134 
Final R indexes 
[I>=2σ (I)] 
R1=0.0349 R1=0.0399 R1=0.0272 R1=0.0264 R1=0.0282 
 wR2=0.0936 wR2=0.1114 wR2=0.0946 wR2=0.0670 wR2=0.0892 




Table 2 IC50 (μM) values of Cu(II) complexes toward the cell lines. 
 Cells MGC80-3 NCI-H460 Hep-G2 SK-OV-3 HL-7702 
Ligand1 19.04±0.43 16.83±0.79 12.52±1.51 13.33±0.97 19.85±0.41 
Ligand2 7.83±0.65 6.71±0.83 6.98±0.36 7.03±0.28 8.41±0.27 
Ligand3 4.12±0.25 4.31±0.47 4.95±0.40 4.39±0.23 6.21±0.26 
Ligand4 3.57±0.17 3.98±0.51 3.49±0.33 3.75±0.19 4.28±0.37 
Ligand5 4.32±0.31 4.49±0.72 5.58±0.57 4.51±0.41 7.15±0.46 
C1 12.11±0.82 11.57±1.25 6.81±1.35 7.93±0.73 13.37±1.85 
C2 1.30±0.47 1.52±0.48 1.78±0.43 1.92±0.45 2.39±0.27 
C3 1.09±0.42 1.39±0.37 1.60±0.46 1.26±0.47 1.76±0.35 
C4 0.84±0.49 1.28±0.46 1.31±0.24 1.18±0.44 1.68±0.45 
C5 1.11±0.33 1.43±0.34 1.69±0.47 1.29±0.48 2.08±0.44 
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